Alembic Pharmaceuticals Limited
NSE: APLLTD BSE: APLLTD
NSE
960.10
4.35 (0.46%)
Prev Close
955.75
Open Price
960
Volume
164,551
Today Low / High
950.75 / 968.45
52 WK Low / High
725.2 / 1303.9
Range
912 - 1,008
BSE
959.95
3.80 (0.40%)
Prev Close
956.15
Open Price
959.6
Volume
1,957
Today Low / High
950.45 / 967.3
52 WK Low / High
725.6 / 1296.15
Range
912 - 1,008
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 960.1 (target range: 912 - 1,008), reflecting a change of 4.35 (0.45514%). On the BSE, it is listed at 959.95 (target range: 912 - 1,008), showing a change of 3.8 (0.39743%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
04 Sep
960.00
0.01%
03 Sep
943.95
1.25%
02 Sep
942.70
0.13%
01 Sep
931.00
1.26%
29 Aug
931.10
0.63%
28 Aug
944.90
-1.01%
26 Aug
970.00
-3.45%
25 Aug
974.90
0.32%
22 Aug
962.10
1.30%
21 Aug
982.00
-1.44%
20 Aug
1,002.00
-1.97%
19 Aug
965.10
2.89%
18 Aug
974.00
-0.24%
14 Aug
943.05
1.47%
13 Aug
945.00
-0.24%
12 Aug
945.05
0.26%
11 Aug
935.00
1.55%
08 Aug
947.30
-1.17%
Alembic Pharmaceuticals Limited Graph
Alembic Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 960.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 959.95 | 969.55 | 872.59 - 1,066.50 |
| 979.15 | 783.32 - 1,174.98 | ||
| 988.75 | 692.12 - 1,285.37 | ||
| Bearish Scenario | 959.95 | 950.35 | 855.32 - 1,045.39 |
| 940.75 | 752.60 - 1,128.90 | ||
| 931.15 | 651.81 - 1,210.50 |
Overview of Alembic Pharmaceuticals Limited
ISIN
INE901L01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
364,115
Market Cap
188,720,136,300
Last Dividend
11
Official Website
IPO Date
2011-09-20
DCF Diff
59.19
DCF
902
Financial Ratios Every Investor Needs
Stock Dividend of APLLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-29 | July 29, 25 | 11 | 11 | 2025-07-29 | 2025-08-07 | |
| 2024-07-15 | July 15, 24 | 11 | 11 | 2024-07-15 | 2024-08-21 | |
| 2023-07-28 | July 28, 23 | 8 | 8 | 2023-07-28 | 2023-09-03 | |
| 2022-08-17 | August 17, 22 | 10 | 10 | 2022-08-18 | 2022-09-03 | |
| 2021-07-19 | July 19, 21 | 14 | 14 | 2021-07-20 | 2021-07-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,672.08 Cr | 1,793.36 Cr | 4,878.72 Cr | 0.7312 | 0.00 Cr | 280.46 Cr | 3,316.38 Cr | 583.42 Cr | 29.68 | 1,008.23 Cr | 0.0874 |
| 2024-03-31 | 6,228.63 Cr | 3,959.80 Cr | 2,268.83 Cr | 0.3643 | 438.56 Cr | 251.97 Cr | 575.81 Cr | 615.82 Cr | 31.33 | 961.67 Cr | 0.0989 |
| 2023-03-31 | 5,652.62 Cr | 1,708.82 Cr | 3,943.80 Cr | 0.6977 | 29.07 Cr | 241.05 Cr | 437.78 Cr | 341.99 Cr | 17.40 | 711.11 Cr | 0.0605 |
| 2022-03-31 | 5,231.79 Cr | 1,723.19 Cr | 3,508.60 Cr | 0.6706 | 50.59 Cr | 210.98 Cr | 587.47 Cr | 520.94 Cr | 26.50 | 924.62 Cr | 0.0996 |
| 2021-03-31 | 5,276.22 Cr | 1,521.27 Cr | 3,754.95 Cr | 0.7117 | 25.38 Cr | 208.66 Cr | 1,296.84 Cr | 1,146.50 Cr | 59.18 | 1,567.57 Cr | 0.2173 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 7,772.94 Cr | 2,583.42 Cr | 5,190.9400 Cr | 1,257.50 Cr | 1,167.40 Cr | 2,288.14 Cr | 3,360.76 Cr | 0.00 Cr | 0.00 Cr | 127.21 Cr | 2,412.3300 Cr |
| 2024-03-31 | 120.21 Cr | 6,445.58 Cr | 1,627.38 Cr | 4,818.2000 Cr | 513.16 Cr | 392.95 Cr | 1,643.54 Cr | 3,071.05 Cr | 0.00 Cr | 0.00 Cr | 93.02 Cr | 1,455.0000 Cr |
| 2023-03-31 | 75.48 Cr | 6,182.83 Cr | 1,812.36 Cr | 4,370.4700 Cr | 722.02 Cr | 646.54 Cr | 1,475.27 Cr | 2,999.73 Cr | 218.79 Cr | -83.14 Cr | 96.33 Cr | 1,636.9300 Cr |
| 2022-03-31 | 61.09 Cr | 7,122.03 Cr | 1,884.48 Cr | 5,237.5500 Cr | 717.11 Cr | 656.02 Cr | 1,609.70 Cr | 3,947.26 Cr | 365.18 Cr | -197.69 Cr | 118.40 Cr | 1,716.5300 Cr |
| 2021-03-31 | 98.06 Cr | 6,708.98 Cr | 1,642.01 Cr | 5,127.6100 Cr | 583.61 Cr | 485.55 Cr | 1,486.15 Cr | 3,648.03 Cr | 299.87 Cr | 85.52 Cr | 49.31 Cr | 1,280.8400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 87.9700 Cr | -568.4100 Cr | 443.7100 Cr | -475.6500 Cr | -36.7300 Cr | 83.4800 Cr | -563.6200 Cr | 583.4200 Cr | 765.1200 Cr | -216.2200 Cr | -644.6000 Cr |
| 2024-03-31 | 803.2000 Cr | -320.6100 Cr | -437.8700 Cr | 475.7300 Cr | 44.7300 Cr | 120.2100 Cr | -327.4700 Cr | 615.8200 Cr | -205.4100 Cr | -157.2500 Cr | -168.2800 Cr |
| 2023-03-31 | 723.9500 Cr | -447.5900 Cr | -261.9600 Cr | 280.5400 Cr | 14.3900 Cr | 75.4800 Cr | -443.4100 Cr | 354.5900 Cr | 5.8700 Cr | -196.5600 Cr | 134.4400 Cr |
| 2022-03-31 | 552.3500 Cr | -371.9700 Cr | -217.3500 Cr | 126.7100 Cr | -36.9700 Cr | 61.0900 Cr | -425.6400 Cr | 620.1100 Cr | 129.9800 Cr | -275.1900 Cr | -123.5500 Cr |
| 2021-03-31 | 1,463.3800 Cr | -838.8100 Cr | -597.4300 Cr | 803.8700 Cr | 26.2200 Cr | 98.0600 Cr | -659.5100 Cr | 1,368.0800 Cr | -397.9900 Cr | 0.0000 Cr | -298.6200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,710.72 Cr | 407.41 Cr | 1,303.31 Cr | 0.7618 | 207.58 Cr | 154.38 Cr | 7.85 | 287.39 Cr | 0.0902 |
| 2025-03-31 | 1,769.64 Cr | 530.61 Cr | 1,239.03 Cr | 0.7002 | 845.44 Cr | 156.89 Cr | 7.98 | 272.59 Cr | 0.0887 |
| 2024-12-31 | 1,692.74 Cr | 439.54 Cr | 1,253.20 Cr | 0.7403 | 190.18 Cr | 138.42 Cr | 7.01 | 270.08 Cr | 0.0818 |
| 2024-09-30 | 1,647.98 Cr | 429.12 Cr | 1,218.86 Cr | 0.7396 | 168.75 Cr | 153.41 Cr | 7.79 | 269.74 Cr | 0.0931 |
| 2024-06-30 | 1,561.73 Cr | 842.90 Cr | 718.83 Cr | 0.4603 | 167.79 Cr | 134.71 Cr | 6.84 | 238.93 Cr | 0.0863 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 0.00 Cr | 90.10 Cr | 1,399.79 Cr | 2,288.14 Cr | 4,087.80 Cr | 3,360.76 Cr | 7,772.94 Cr | 2,583.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 128.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,887.64 Cr |
| 2024-09-30 | 122.05 Cr | 27.22 Cr | 149.27 Cr | 1,267.68 Cr | 2,012.52 Cr | 3,762.39 Cr | 3,124.86 Cr | 7,230.25 Cr | 2,342.61 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | -4,818.20 Cr |
| 2024-03-31 | 126.57 Cr | 27.13 Cr | 126.57 Cr | 1,024.84 Cr | 1,643.54 Cr | 3,078.56 Cr | 3,071.07 Cr | 6,445.58 Cr | 1,627.38 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 156.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 138.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 153.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 178.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,582.30 | ₹3,796,380,744,000.00 | ₹2,298,318.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,133.50 | ₹1,628,254,111,500.00 | ₹294,428.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,599.30 | ₹1,218,165,088,500.00 | ₹128,391.00 |
| Mankind Pharma Limited | MANKIND | ₹2,568.90 | ₹1,060,258,911,564.00 | ₹421,457.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,253.00 | ₹1,042,912,089,975.00 | ₹1,230,895.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,011.95 | ₹1,018,254,448,500.00 | ₹1,037,917.00 |
| Lupin Limited | LUPIN | ₹1,939.20 | ₹885,723,782,400.00 | ₹382,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,301.50 | ₹633,873,847,500.00 | ₹131,757.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,036.00 | ₹601,710,872,000.00 | ₹422,287.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,990.90 | ₹561,833,970,900.00 | ₹493,142.00 |
| Laurus Labs Limited | LAURUSLABS | ₹874.10 | ₹471,861,032,500.00 | ₹988,966.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹899.30 | ₹344,042,510,294.00 | ₹1,313,965.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,339.20 | ₹339,760,396,800.00 | ₹325,213.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,600.70 | ₹324,921,055,200.00 | ₹125,198.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,723.40 | ₹269,636,270,400.00 | ₹32,494.00 |
| Piramal Enterprises Limited | PEL | ₹1,077.50 | ₹244,245,545,000.00 | ₹315,535.00 |
| Eris Lifesciences Limited | ERIS | ₹1,763.60 | ₹240,214,665,200.00 | ₹67,677.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,475.90 | ₹239,802,756,100.00 | ₹309,681.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,113.00 | ₹227,825,000,000.00 | ₹20,690.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹960.10 | ₹188,720,136,300.00 | ₹164,551.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹14,612.00 | ₹187,470,498,800.00 | ₹56,187.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,064.80 | ₹169,602,408,800.00 | ₹135,897.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,117.00 | ₹160,916,768,900.00 | ₹38,649.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹855.55 | ₹153,237,560,500.00 | ₹378,755.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹512.85 | ₹124,439,975,400.00 | ₹812,341.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,462.00 | ₹107,265,322,800.00 | ₹16,618.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹841.95 | ₹82,335,048,255.00 | ₹53,042.00 |
| Strides Pharma Science Limited | STAR | ₹883.25 | ₹81,411,537,275.00 | ₹214,868.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹881.20 | ₹79,867,227,144.00 | ₹270,578.00 |
| FDC Limited | FDC | ₹460.35 | ₹74,949,583,500.00 | ₹51,828.00 |
| Innova Captab Limited | INNOVACAP | ₹918.80 | ₹52,578,265,684.00 | ₹22,465.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹144.32 | ₹46,835,015,040.00 | ₹222,056.00 |
| Suven Life Sciences Limited | SUVEN | ₹211.67 | ₹46,159,723,580.00 | ₹79,491.00 |
| Sequent Scientific Limited | SEQUENT | ₹177.12 | ₹44,339,335,200.00 | ₹258,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹474.35 | ₹43,293,924,500.00 | ₹111,389.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,373.80 | ₹39,260,278,200.00 | ₹6,166.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹721.60 | ₹36,598,902,560.00 | ₹25,058.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹364.50 | ₹36,551,331,000.00 | ₹350,243.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹501.65 | ₹35,319,069,570.00 | ₹7,648.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹666.25 | ₹32,081,936,250.00 | ₹102,989.00 |
| Hikal Limited | HIKAL | ₹259.75 | ₹32,027,434,750.00 | ₹266,490.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹98.19 | ₹28,821,416,130.00 | ₹1,520,814.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.52 | ₹27,134,682,080.00 | ₹4,438,774.00 |
| Alembic Limited | ALEMBICLTD | ₹104.10 | ₹26,731,006,096.00 | ₹333,742.00 |
Key Executives
MD & Executive Director
Mr. Shaunak Chirayu Amin
Gender: male
Year Born: 1978
Director of Finance, Chief Financial Officer & Executive Director
Mr. Raj Kumar Shreeram Baheti B.Com.(Hon.), FCA, FCS
Gender: male
Year Born: 1959
Chief Scientific Officer
Dr. J. Venkat Raman M. S., Ph.D.
Gender: Not Specified
Year Born: 1958
Company Secretary & Compliance Officer
Ms. Manisha Saraf
Gender: female
Year Born:
Managing Director
Mr. Pranav Chirayu Amin
Gender: male
Year Born: 1975
Head of Technical Operations
Mr. Sudhakar Pandiyan
Gender: male
Year Born:
Chief Business Development Officer
Mr. Udit C. Amin
Gender: male
Year Born: 1980
Senior Vice President
Mr. Gautam Chatterjee
Gender: male
Year Born: 1961
Executive Chairman & Chief Executive Officer
Mr. Chirayu Ramanbhai Amin
Gender: male
Year Born: 1946
Senior Vice President of Finance
Mr. Ajay Kumar Desai
Gender: male
Year Born:
FAQs about Alembic Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Chirayu Ramanbhai Amin.
What is the current market price of the stock?
The current price is ₹960.10.
What is the 52-week price range?
The range is ₹725.2-1303.9.
What is the market capitalization of the company?
The market capitalization is ₹18,872.01 crores.
What is the dividend yield?
The dividend yield is 1.15%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 31.31.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Pharmaceuticals Limited (ISIN: INE901L01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹18,872.01 crores and an average daily volume of 364,115 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.